Article
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Nature communications - 6 Mar 2020
Bajpai Richa, Sharma Aditi, Achreja Abhinav, Edgar Claudia L, Wei Changyong, Siddiqa Arusha A, Gupta Vikas A, Matulis Shannon M, McBrayer Samuel K, Mittal Anjali, Rupji Manali, Barwick Benjamin G, Lonial Sagar, Nooka Ajay K, Boise Lawrence H, Nagrath Deepak, Shanmugam Mala
Abstract excerpt
The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has reduced mitochondrial respiration. Consistent with this, low electron transport chain (ETC) Complex I and Complex II...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
